株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

眼科薬剤の将来動向

Ophthalmology Drug Futures

発行 Espicom Business Intelligence 商品コード 189477
出版日 ページ情報 英文 118 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。
Back to Top
眼科薬剤の将来動向 Ophthalmology Drug Futures
出版日: 2011年04月12日 ページ情報: 英文 118 Pages
概要

加齢性黄斑変性症(AMD)の治療に用いられる薬剤市場は33億米ドル規模と見積もられています。参入企業が少なく患者数が増加していることから、中期的に引き続き成長が見込まれています。緑内障は世界で6,500万人〜7,000万人の患者がおり、白内障に続き失明の原因第2位となっています。WHOによると、2002年の失明の12.3%が緑内障によるものといわれています。一方、緑内障およびAMDとともに、ドライアイも大きな問題となりつつあり、年齢とともに増加しています。OTC薬として入手可能な人工涙液で治療されていますが、処方薬市場は15億米ドルとなっています。

当レポートでは、これら3つの眼科疾患に関する市場について分析し、これらの治療法、必要とされている新たな治療法、上市製品および開発中の製品概要などをまとめ、概略下記の構成でお届けいたします。

序文

エグゼクティブサマリー

市場概要

  • 研究開発サマリー
  • 競合比率分析
  • 背景情報
    • 高齢化における眼病

加齢性黄斑変性症

  • 市場分析
  • 黄斑変性症とは
  • 治療法
  • 必要とされる新たな治療法
  • 開発製品
  • 有病率
  • 確立されている製品
    • Lucentis
    • Macugen
    • Visudyne
  • 第3相
    • VEGF-Trap-Eye
  • 第2相
    • ACU-4429
    • PF-4523655

緑内障

  • 市場分析
  • 緑内障とは
  • 治療法
  • 必要とされる新たな治療法
  • 開発製品
  • 有病率
  • 確立されている製品
    • Alphagan
    • Trusopt
    • Azopt
    • Xalatan
    • Lumigan
    • Travatan
    • Saflutan
  • 第2相
    • Taprenepag
    • BOL-303259-X
    • AR-12286
  • 第1/2相
    • INO-8875

ドライアイ症候群

  • 市場分析
  • ドライアイ症候群とは
  • 治療法
  • 必要とされる新たな治療法
  • 開発製品
  • 有病率
  • 上市済み製品
    • Restasis
    • Hyalein
    • Diquas
  • 開発中の新たな処方
    • Remura
    • Mucosta
  • 第2/3相
    • CF101
  • 第2相
    • Tofacitinib

調査方法

情報源

目次

Abstract

An expanding market with high unmet clinical need and huge commercial opportunity

Covering:

  • Glaucoma
  • Age-related Macular
  • Dry Eye Syndrome

A complete and practical analysis of Ophthalmology Drugs packed with facts, figures and forecasts for launched and late-stage products.

The US$14 billion global ophthalmology sector faces both commercial challenge and clinical opportunity, and this report answers key questions:

  • Why are we interested in chronic eye diseases?
  • Driven by ageing populations, which markets are expected to see the highest growth in the 65+ age groups?
  • Which sectors of the market are anticipated to contract by value over the next five years?
  • What new products will be launched over the next 5 years and what impact will they have on the market?
  • Which companies are set to improve their market share?
  • What novel products are in development for Wet Age-related Macular Degeneration (AMD)?
  • Dry AMD - large unmet clinical need, but what is the potential?
  • What potential benefits does Bayer' s VEGF Trap-Eye Regeneron have over existing treatments?
  • Merck' s NDA for Saflutan was submitted to FDA in March 2011 - what impact on the market could this product have?
  • Why are new treatments needed for dry eye?

Sight preservation in chronic eye disease is a high yielding, valuable and expanding sector in developed and emerging markets.

GLAUCOMA

Glaucoma affects around 65-70 million people worldwide and is the second leading cause of blindness, after cataracts. The WHO estimates that glaucoma was responsible for around 12.3% of world blindness in 2002, affecting around five million people.

Undoubtedly, generic companies will claim a significant share of the US$4.9 billion glaucoma market over the next few years. Pfizer' s US patent for the market leader, Xalatan (latanoprost) expired in March 2011 and the first generics have been approved.

Others in this segment are also set to lose exclusivity over the next few years. Dependent on the outcome of patent litigation, Alcon' s Travatan Z (travoprost) could face generic competition in the US as early as December 2011. Allergan' s US patents for Lumigan (bimatoprost) will expire in 2012 and 2014, while the European patents are set to expire in various markets between 2013 and 2017.

In the short term, there may be new competition in the US if Merck & Co is successful in gaining approval for Saflutan (tafluprost). Merck & Co has a licensing agreement for the product with Santen Pharmaceutical who market it in some Asian/European markets. Beyond new formulations and combination products in Phase III, the most advanced novel agents have yet to progress beyond Phase II.

The report covers

  • Market analysis
  • What is glaucoma?
  • How is it treated?
  • Why are new treatments needed?
  • What is in development?
  • Glaucoma prevalence

Launched products

  • Alphagan (brimonidine)
  • Trusopt (dorzolamide)
  • Azopt (brinzolamide)
  • Xalatan (latanoprost)
  • Lumigan (bimatoprost)
  • Travatan (travoprost)
  • Saflutan (tafluprost)

Phase II

  • BOL-303259-X
  • AR-12286

Phase I/II

  • INO-8875

AGE-RELATED MACULAR DEGENERATION

The market for drugs used to treat wet age-related macular degeneration (AMD) is estimated to be worth US$3.3 billion. There are relatively few players and an increasing patient pool; continued growth is expected over the medium term.

The current standard of care for wet AMD is Lucentis (ranibizumab), marketed by Roche in the US and Novartis elsewhere. Growth has been impressive since its launch in 2006; global sales amounted to US$3 billion in 2010. The cost of treatment is high, however, and there is some competition from off-label use of Roche' s Avastin (bevacizumab), which is significantly cheaper. In the US, the National Eye Institute is conducting a major Phase III comparative study of Avastin and Lucentis for the treatment of AMD.

But there is new competition expected on the market. The most advanced developmental treatment for AMD is Bayer and Regeneron' s VEGF Trap-Eye. Following positive top-line results from Phase III trials, regulatory filings have been planned in the US and EU in 2011. If approved, it is expected that this product will be quickly taken up in the market-place. It appears to have similar efficacy to Lucentis with less frequent dosing, which is likely to prove popular among patients and healthcare providers alike.

The report covers

  • Market analysis
  • What is macular degeneration?
  • How is it treated?

Photodynamic Therapy Anti-VEGF

  • Why are new treatments needed?
  • What is in development?
  • AMD prevalence

Launched products

  • Lucentis (ranibizumab)
  • Macugen (pegaptanib)
  • Visudyne (verteporfin)

Phase III

  • VEGF Trap-Eye

Phase II

  • ACU-4429
  • PF-4523655

DRY EYE SYNDROME

Alongside glaucoma and AMD, dry eye is a growing problem and one that also increases with age. While this condition is widely treated with artificial tear products that are available over the counter, the prescription market is currently worth around US$1.5 billion.

There are relatively few prescription pharmaceuticals to treat more severe cases; in the US, Allergan' s Restasis (ciclosporin) ophthalmic emulsion is currently the only product approved to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation. Competition may be on the horizon, however, from ISTA Pharmaceuticals' Remura (bromfenac), which is in Phase III for the condition.

The report covers

  • Market analysis
  • What is dry eye syndrome?
  • How is it treated?
  • Why are new treatments needed?
  • What is in development?
  • Dry eye prevalence

Launched products

  • Restasis (ciclosporin)
  • Hyalein (sodium hyaluronate)
  • Diquas (diquafosol)

New formulations in development

  • Remura (bromfenac)
  • Mucosta (rebamipide)

Phase II/III

  • CF101

Phase II

  • Tofacitinib

About the Author

The report has been researched and written by Espicom' s Senior Analyst, Karen Holmes. Karen has over 15 years pharmaceutical and healthcare market analysis experience.

Report Statistics

  • Date Published: April 12th 2011
  • Total Number of Pages: 118
  • Available Formats: PDF and Paper

Table of Contents

  • FOREWORD
  • EXECUTIVE SUMMARY
  • MARKET OVERVIEW
  • RESEARCH & DEVELOPMENT SUMMARY
  • COMPETITOR RATIO ANALYSIS
  • BACKGROUND INFORMATION
    • Eye Disease in an Ageing Population
  • AGE-RELATED MACULAR DEGENERATION
  • MARKET ANALYSIS
  • WHAT IS MACULAR DEGENERATION?
  • HOW IS IT TREATED?
    • Photodynamic Therapy
    • Anti-VEGF
  • WHY ARE NEW TREATMENTS NEEDED?
  • WHAT IS IN DEVELOPMENT?
  • AMD PREVALENCE
  • ESTABLISHED PRODUCTS
    • Lucentis (ranibizumab)
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market
      • Competitor Ratio Analysis
      • Sales Forecast
      • Clinical Trial Results
    • Macugen (pegaptanib)
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market
      • Competitor Ratio Analysis
      • Clinical Trial Results
    • Visudyne (verteporfin)
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market
      • Competitor Ratio Analysis
      • Clinical Trial Results
  • PHASE III
    • VEGF Trap-Eye
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market
      • Competitor Ratio Analysis
      • Sales Forecast
      • Clinical Trial Results
  • PHASE II
    • ACU-4429
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market
      • Competitor Ratio Analysis
    • PF-4523655
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
    • Company Expertise
    • Competition within the Market
    • Competitor Ratio Analysis
  • GLAUCOMA
  • MARKET ANALYSIS
  • WHAT IS GLAUCOMA?
  • HOW IS IT TREATED?
    • Open-Angle Glaucoma and Ocular Hypertension
    • Pharmacological Treatments
    • Laser Treatment/Surgery
  • Angle-Closure Glaucoma
    • Pharmacological Intervention
    • Laser Treatment/Surgery
  • WHY ARE NEW TREATMENTS NEEDED?
  • WHAT IS IN DEVELOPMENT?
  • GLAUCOMA PREVALENCE
  • ESTABLISHED PRODUCTS
    • Alphagan (brimonidine)
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market
      • Competitor Ratio Analysis
      • Sales Forecast
    • Trusopt (dorzolamide)
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market
      • Competitor Ratio Analysis
      • Sales Forecast
    • Azopt (brinzolamide)
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market
      • Competitor Ratio Analysis
      • Sales Forecast
    • Xalatan (latanoprost)
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market
      • Competitor Ratio Analysis
      • Sales Forecast
    • Lumigan (bimatoprost)
      • Mechanism of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market
      • Clinical Trial Results
      • Competitor Ratio Analysis
      • Sales Forecast
    • Travatan (travoprost)
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market
      • Competitor Ratio Analysis
      • Sales Forecast
    • Saflutan (tafluprost)
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market
      • Competitor Ratio Analysis
      • Sales Forecast
  • PHASE II
    • Taprenepag
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market
      • Competitor Ratio Analysis
      • Clinical Trial Results
    • BOL-303259-X
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market
      • Competitor Ratio Analysis
    • AR-12286
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition with the Market
      • Competitor Ratio Analysis
      • Clinical Trial Results
  • PHASE I/II
    • INO-8875
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market
      • Competitor Ratio Analysis
  • DRY EYE SYNDROME
  • MARKET ANALYSIS
  • WHAT IS DRY EYE SYNDROME?
  • HOW IS IT TREATED?
  • WHY ARE NEW TREATMENTS NEEDED?
  • WHAT IS IN DEVELOPMENT?
  • DRY EYE PREVALENCE
  • LAUNCHED PRODUCTS
    • Restasis (ciclosporin)
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market
      • Competitor Ratio Analysis
      • Sales Forecast
    • Hyalein (sodium hyaluronate)
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market
      • Competitor Ratio Analysis
      • Sales Forecast
    • Diquas (diquafosol)
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market
      • Competitor Ratio Analysis
  • NEW FORMULATIONS IN DEVELOPMENT
    • Remura (bromfenac)
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition with the Market
      • Competitor Ratio Analysis
      • Clinical Trial Results
    • Mucosta (rebamipide)
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market
      • Competitor Ratio Analysis
  • PHASE II/III
    • CF101
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market
      • Competitor Ratio Analysis
      • Clinical Trial Results
  • PHASE II
    • Tofacitinib
      • Mode of Action
      • Current Status
      • Proof of Concept/Clinical Data
      • Development Risks
      • Company Expertise
      • Competition within the Market
      • Competitor Ratio Analysis
  • METHODOLOGY
    • Competitor Ratio Analysis Criteria
    • Drug Sales Forecasting
  • SOURCES

List of Tables

  • Company Overview
  • Drugs in Clinical Development
  • Competitor Ratio Analysis Summary
  • Sales of Leading Eye Care Pharmaceuticals, 2009-2016 (US$ Million)
  • Male Life Expectancy at Birth (Years), 2005-2009
  • Female Life Expectancy at Birth (Years), 2005-2009
  • Leading AMD Drug Sales, 2005-2010 (US$ Million)
  • AMD Market Share by Company, 2010 (%)
  • Drugs in Clinical Development for Age-related Macular Degeneration
  • Lucentis Sales by Company, 2009-2016 (US$ Million)
  • Final RADICAL outcomes (24 months)
  • Leading Glaucoma Drug Sales, 2005-2010 (US$ Million)
  • Drugs in Clinical Development for Glaucoma
  • Alphagan/Combigan Sales, 2009-2016 (US$ Million)
  • Trusopt/Cosopt Sales, 2009-2016 (US$ Million)
  • Xalatan/Xalacom Sales, 2009-2016 (US$ Million)
  • Lumigan Sales, 2009-2016 (US$ Million)
  • Leading Dry Eye Prescription Drug Sales, 2005-2010 (US$ Million)
  • Drugs in Clinical Development for Dry Eye Syndrome
  • Restasis Sales, 2009-2016 (US$ Million)
  • Hyalein Sales, 2009-2016 (US$ Million)

List of Figures

  • Ophthalmology Market Sectors, 2010 (%)
  • Market Share by Company, 2010 (%)
  • Ophthalmology Market Sectors, 2016 (%)
  • Market Share by Company, 2016 (%)
  • Life Expectancy at Birth, 2008
  • Population Aged 65+ by Country, 2005 and 2020 (%)
  • Population Aged 65+, 2005-2020 (Millions)
  • Market Share of Leading AMD Drugs, 2010 (%)
  • How AMD Affects the Eye
  • Lucentis Sales, 2007-2016 (US$ Million)
  • VEGF Trap-Eye Sales, 2012-2016 (US$ Million)
  • Market Share of Leading Glaucoma Drugs, 2010 (%)
  • Glaucoma Market Share by Company, 2010 (%)
  • Diagram of a Healthy Eye
  • How Glaucoma Affects the Eye
  • Alphagan/Combigan Sales, 2007-2016 (US$ Million)
  • Trusopt/Cosopt Sales, 2007-2016 (US$ Million)
  • Azopt/Azarga Sales, 2009-2016 (US$ Million)
  • Xalatan/Xalacom Sales, 2007-2016 (US$ Million)
  • Lumigan Sales, 2007-2016 (US$ Million)
  • Travatan/Travatan Z Sales, 2009-2016 (US$ Million)
  • Saflutan/Tapros Sales, 2008-2016 (US$ Million)
  • Market Share of Leading Dry Eye Prescription Drugs, 2010 (%)
  • Dry Eye Market Share by Company, 2010 (%)
  • Restasis Sales, 2007-2016 (US$ Million)
  • Hyalein Sales, 2007-2016 (US$ Million)
Back to Top